Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Robert Haddad, Ezra E.W. Cohen, Meena Venkatachalam, Kate Young, Prianka Singh, James W. Shaw, Beata Korytowsky, Pranav Abraham & Kevin J. Harrington. (2020) Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. Journal of Medical Economics 23:5, pages 442-447.
Read now
Read now
Frank G. Sandmann, Sarah Mostardt, Stefan K. Lhachimi & Andreas Gerber-Grote. (2018) The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 475-486.
Read now
Read now
Maria Kamusheva, Konstantin Tachkov, Guenka Petrova, Alexandra Savova & Manoela Manova. (2018) Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles. Expert Opinion on Orphan Drugs 6:2, pages 95-104.
Read now
Read now
Articles from other publishers (17)
Nicolas S. H. Xander, W. Edward Fiets & Carin A. Uyl-de Groot. (2023) Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands. Frontiers in Oncology 13.
Crossref
Crossref
Shwetabh Sinha, Sarbani Ghosh Laskar, Tabassum Wadasadawala, Rahul Krishnatry, Yolande Lievens & Jai Prakash Agarwal. (2022) Adopting Health Economic Research in Radiation Oncology: A Perspective From Low- or Middle-Income Countries. JCO Global Oncology:8.
Crossref
Crossref
Bettina M. Zimmermann, Johanna Eichinger & Matthias R. Baumgartner. (2021) A systematic review of moral reasons on orphan drug reimbursement. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Luca Pani & Karin Becker. (2021) New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. Clinical Drug Investigation 41:6, pages 529-537.
Crossref
Crossref
Xin Zhang, Hang Liao, Di Shi, Xinran Li, Xiaoping Chen & Sen He. (2019) Cost-effectiveness analysis of different hypertension management strategies in a community setting. Internal and Emergency Medicine 15:2, pages 241-250.
Crossref
Crossref
Ewa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec, Rafał Bobiński, Jacek Siwiec, Dimitra Panteli, Helene Eckhardt, Steven Simoens, Antònia Agusti, Marc Dooms & Andrzej Pilc. (2019) Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries. Frontiers in Pharmacology 10.
Crossref
Crossref
Georgi Iskrov, Dan Greenberg, Ivan Yakimov, Hristina Cholakova & Rumen Stefanov. (2019) What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. Value in Health Regional Issues 19, pages 157-162.
Crossref
Crossref
Mónica D. Oliveira, Inês Mataloto & Panos Kanavos. (2019) Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. The European Journal of Health Economics 20:6, pages 891-918.
Crossref
Crossref
Bengt Jönsson, Grace Hampson, Jonathan Michaels, Adrian Towse, J.-Matthias Graf von der Schulenburg & Olivier Wong. (2018) Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. The European Journal of Health Economics 20:3, pages 427-438.
Crossref
Crossref
Evelyn Walter. 2019. Regulatory and Economic Aspects in Oncology. Regulatory and Economic Aspects in Oncology
85
108
.
Huey Yi Chong, Pascale A. Allotey & Nathorn Chaiyakunapruk. (2018) Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Medical Genomics 11:1.
Crossref
Crossref
Cássia Rita Pereira da Veiga, Claudimar Pereira da Veiga & Ana Paula Drummond-Lage. (2018) Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. Critical Reviews in Oncology/Hematology 129, pages 133-145.
Crossref
Crossref
Valérie Paris. (2018) Le coût des anti-cancéreux : un défi pour les systèmes de santé des pays de l’OCDE. Bulletin de l'Académie Nationale de Médecine 202:5-6, pages 989-1002.
Crossref
Crossref
Praveen Thokala, Jessica Ochalek, Ashley A. Leech & Thaison Tong. (2018) Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 36:5, pages 509-522.
Crossref
Crossref
Pricivel Carrera & S. Yousuf Zafar. 2018. The MASCC Textbook of Cancer Supportive Care and Survivorship. The MASCC Textbook of Cancer Supportive Care and Survivorship
127
143
.
Chadi Nabhan & Bruce A. Feinberg. (2017) Value-Based Calculators in Cancer: Current State and Challenges. Journal of Oncology Practice 13:8, pages 499-506.
Crossref
Crossref
Maarten J. IJzerman, Hendrik Koffijberg, Elisabeth Fenwick & Murray Krahn. (2017) Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. PharmacoEconomics 35:7, pages 727-740.
Crossref
Crossref